Zevra Therapeutics (ZVRA) Cash & Current Investments (2014 - 2026)

Zevra Therapeutics' Cash & Current Investments history runs 13 years deep, the most recent figure standing at $200.6 million for Q1 2026.

• Quarterly Cash & Current Investments rose 220.31% year-over-year to $200.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $200.6 million (up 220.31% YoY) and the FY2025 annual result came in at $191.0 million, up 174.85% from the prior year.
• Cash & Current Investments was $200.6 million for Q1 2026 at Zevra Therapeutics, up from $191.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $202.6 million in Q2 2025 and bottomed at $479000.0 in Q2 2023.
• A 5-year average of $92.6 million and a median of $68.6 million in 2023 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2023 — Cash & Current Investments tumbled 99.38% — and 2024, when it surged 10183.51%.
• Zevra Therapeutics' Cash & Current Investments stood at $65.9 million in 2022, then advanced by 2.71% to $67.7 million in 2023, then gained by 2.6% to $69.5 million in 2024, then jumped by 174.85% to $191.0 million in 2025, then grew by 5.03% to $200.6 million in 2026.
• Business Quant data shows ZVRA's Cash & Current Investments at $200.6 million in Q1 2026, $191.0 million in Q4 2025, and $199.5 million in Q3 2025.